stockrow
Saturday 7 November 2026
Export ADTX’s income statement to Excel — free account
Aditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024.
- Revenue
- +1,120.0%
- EPS
- +99.6%
- Free cash flow
- +60.8%
Quarter to March 2026, against a year earlier
0.00
0.00
NaN
Follow ADTX
Alert me
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 3 | 4 |
+8 more TTM periods Free account |
| 549.59% | (1,708.64%) | 1,915.52% | (338.55%) | ||
| (236.38%) | (177.15%) | (202.88%) | (101.67%) | ||
ROIC |
0.00% | (1,619.88%) | 0.00% | (118.41%) | |
Return on Tangible Assets |
456.62% | 573.29% | 223.57% | 165.67% | |
Average Days of Receivables |
306.29 | 0.00 | 11,642.88 | 1,197.56 | |
Free Cash Flow per Share |
(920.15) | (4,929.08) | (112,948.50) | (262,564.16) | |
Free Cash Flow |
(18.59) | (25.71) | (22.59) | (22.61) | |
Capital Expenditures |
(0.03) | (0.02) | — | — | |
| Other line items | |||||
Cash ROIC |
53.25% | (359.49%) | 259.77% | (183.54%) | |
Accounts Receivable Turnover |
0.02 | 0.00 | 0.01 | 0.05 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.01 | 0.05 | |
Inventory Turnover |
0.17 | 0.34 | 1.54 | 1.89 | |
Average Days of Payables |
251,304.09 | 968,307.24 | 57,475.57 | 7,202.84 | |
Days of Inventory on Hand |
4,075.30 | 730.00 | 32.82 | 5.14 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
21,202.80% | 103,035.48% | 56,635.59% | 26,124.79% | |
Selling, General and Administrative Expense of Revenue |
106,960.14% | 528,287.10% | 290,562.71% | 152,259.50% | |
Share Based Compensation of Revenue |
3,309.79% | 15,590.32% | 8,264.41% | 4,030.58% | |
Interest Coverage |
(33.27) | (28.73) | (49.00) | (27.20) | |
Operating CF/Net income |
0.35 | 0.60 | 0.53 | 0.73 | |
Depreciation/Fixed assets |
1.93 | 2.00 | 1.55 | 2.65 | |
Capex/Depreciation |
(0.02) | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
0.71 | 0.59 | 29.50 | 140.52 | |
Operating CF per Share |
(918.50) | (4,924.65) | (112,948.50) | (262,564.16) | |
Capex per Share |
(1.65) | (4.43) | 0.00 | 0.00 | |
Capex to Sales |
2.34 | 7.45 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026